Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSLN STAR-T cells
- Development stage
- Phase 1
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
MSLN STAR-T cells are autologous T cells genetically engineered to express a chimeric antigen receptor (CAR) that specifically targets mesothelin (MSLN), a glycoprotein overexpressed in many solid tumors such as ovarian, lung, and mesothelioma. The "STAR" in the name refers to a specific design or tuning of the CAR construct to optimize activation potential and persistence. These modified T cells are infused intravenously into patients with advanced MSLN-positive solid tumors. The therapy aims to enhance antitumor activity while reducing T cell exhaustion by calibrating CAR signaling domains—such as using a mutated CD3ζ chain containing a single ITAM—to improve efficacy and durability in the immunosuppressive tumor microenvironment[1][2][3][5]. This approach is under investigation for its safety and effectiveness in clinical trials.
- Brand names
- MSLN STAR-T
- Other names
- mesothelin STAR-T cellsmesothelin-targeted STAR-T cells
02
Targets
Mesothelin
Beyond the preview
Go deeper on MSLN STAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSLN STAR-T cells.